Vimta Labs Limited (VIMTALABS) Fair Value & Analysis
Healthcare · IN · Market cap ₹26.2B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +14.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹379.30 – ₹873.97 · fair‑value band ₹212.62 – ₹477.19 · the ₹585.45 price screens above the ₹381.75 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vimta Labs Limited (VIMTALABS) currently trades at ₹585.45, while our model-based Fair Value estimate is ₹381.75 — implying the stock looks roughly 34.8% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Vimta Labs Limited generated revenue of ₹4.1B at a net margin of 18.9%. Revenue grew 16.5% year over year. It earns a return on equity of 18.6%. The balance sheet holds a net cash position of ₹617M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Vimta Labs Limited reported revenue of ₹4.1B in FY2026 versus ₹2.8B in FY2022, a compound +10.2%/yr. Reported net income was ₹775M in FY2026, compounding +17.0%/yr from FY2022.
Is VIMTALABS fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $556.94 | $255.77 | -54% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vimta Labs Limited (VIMTALABS) undervalued?
What is the fair value of VIMTALABS?
What is the quality score of VIMTALABS?
What is the revenue of Vimta Labs Limited (VIMTALABS)?
What is the net profit margin of VIMTALABS?
Does Vimta Labs Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.